FDA Approves Wezlana, First Interchangeable Biosimilar to Stelara

FDA Approves Wezlana, First Interchangable Biosimilar to Stelara

The U.S. Food and Drug Administration (FDA) has approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara for adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; active psoriatic arthritis; moderately to severely active Crohn’s disease; and moderately to severely active ulcerative colitis.

Coming Soon: Dried Plasma for Hemorrhagic Trauma in the Prehospital Setting

Dried Plasma for Hemorrhagic Trauma in the Prehospital Setting

It is now well-established that prehospital transfusion of plasma, with its balanced mix of coagulation proteins, counters the hemodilution and progressive derangement of hemostatic mechanisms caused by crystalloid-based resuscitation, improving the changes of survival in severely bleed trauma victims.

The Future of Orphan Drugs: Advancements, Challenges and Hope

Orphan Drugs

In the realm of healthcare and pharmaceuticals, orphan drugs have emerged as a beacon of hope for individuals suffering from rare diseases. With new technology and AI-driven analytics as drivers, these once-niche therapies are rapidly taking center stage.

Personalized Healthcare

Personalized Medicine - Mining Genomic Sequencing Data

Precise, personal treatment is the way of the future. Here’s how experts are using genetic sequencing to forge a revolutionary new way of practicing medicine.